Glaukos Corporation Common Stock (NY:GKOS)

164.84 -0.76 (-0.46%)

Official Closing Price Updated: 7:00 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup ↗

Today 5:30 EDT

Via Chartmill

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

October 09, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

October 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

October 07, 2026

From Glaukos Corporation

Via Business Wire

Glaukos (NYSE:GKOS) Passes Minervini Trend Template and High-Growth Momentum Screen ↗

September 01, 2026

Via Chartmill

GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill ↗

June 20, 2026

Via Chartmill

Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat ↗

April 29, 2026

Via Chartmill

Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules ↗

April 03, 2026

Via Chartmill

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

October 07, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

September 23, 2026

From Glaukos Corporation

Via Business Wire

If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today ↗

September 10, 2026

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of...

Via Benzinga

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗

August 25, 2026

Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of...

Via Benzinga

Glaukos Announces Participation in Wells Fargo Healthcare Conference

August 19, 2026

From Glaukos Corporation

Via Business Wire

Glaukos (GKOS) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.

Via The Motley Fool

Topics Earnings

Glaukos Q2 Earnings Call Highlights ↗

July 30, 2026

Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth...

Via MarketBeat

Topics Earnings

Glaukos Announces Second Quarter 2026 Financial Results

July 29, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

July 27, 2026

From Glaukos Corporation

Via Business Wire

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? ↗

July 14, 2026

Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.

Via The Motley Fool

Topics Regulatory Compliance

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 08, 2026

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Via The Motley Fool

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

July 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

June 25, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

May 12, 2026

From Glaukos Corporation

Via Business Wire

Glaukos (GKOS) Q1 2026 Earnings Transcript ↗

April 29, 2026

Glaukos (GKOS) Q1 2026 Earnings Transcript

Via The Motley Fool

Glaukos Announces First Quarter 2026 Financial Results

April 29, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces the Release of its 2025 Sustainability Report

April 16, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Receives Permanent J-code for Epioxa™

April 15, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

April 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 06, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

March 19, 2026

From Glaukos Corporation

Via Business Wire

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.